Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
| Traded as | Nasdaq: KYNB |
|---|---|
| ISIN | US31572Q8814 |
| CIK | 0000921299 |
| LEI | 549300Q914ULWWY95822 |
| EIN | 770357827 |
| Sector | Biotechnology |
|---|---|
| Industry | Pharmaceutical Preparations |
| CEO | Thane Wettig |
| Employees | 34 |
| Fiscal Year End | 1231 |
| Address | 350 BAY STREET, SAN FRANCISCO, CA, 94133 |
|---|---|
| Phone | 415-978-1200 |
| Website | http://kyntrabio.com |
Get over a decade of historical stock quotes data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| KYNB | KYNTRA BIO, INC. | 2026-04-02 15:10:04 | 7.01 | 0 | 0 |
Get over a decade of historical company information data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KYNB | 0000921299 | KYNTRA BIO, INC. | US31572Q8814 | 549300Q914ULWWY95822 | 770357827 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 350 BAY STREET | SAN FRANCISCO | CA | 94133 | UNITED STATES | US | 415-978-1200 | 350 BAY STREET, SAN FRANCISCO, CA, 94133 | 350 BAY STREET, SAN FRANCISCO, CA, 94133 | FIBROGEN INC | Biotechnology | 1993 | Thane Wettig | 34 | http://kyntrabio.com | 21,000,000 | 4,047,000 | 4,046,827 | Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. | 2026-04-02 20:02:54 |
Get over a decade of historical stock price data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
Get over a decade of historical stock price data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
Get over a decade of historical market cap data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 21,000,000 | -67,400,000 | -76.2443 | 4,046,827 | -96,870,129 | -95.9899 |
| 2024 | 88,400,000 | -173,100,000 | -66.195 | 100,916,956 | 2,145,709 | 2.1724 |
| 2023 | 261,500,000 | -713,600,000 | -73.1822 | 98,771,247 | 4,588,332 | 4.8717 |
Get over a decade of historical employee count data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 34 |
Get over a decade of historical income statement data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Revenue | 6,440,000 |
| Cost Of Revenue | 556,000 |
| Gross Profit | — |
| Research And Development Expenses | 23,517,000 |
| General And Administrative Expenses | 27,709,000 |
| Operating Expenses | 52,335,000 |
| Operating Income | -45,895,000 |
| Net Income | 183,452,000 |
| Earnings Per Share Basic | 45.37 |
| Earnings Per Share Diluted | 45.37 |
| Weighted Average Shares Outstanding Basic | 4,043,000 |
| Weighted Average Shares Outstanding Diluted | 4,043,000 |
Get over a decade of historical balance sheet statement data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Cash And Cash Equivalents | 47,872,000 |
| Marketable Securities Current | 41,106,000 |
| Accounts Receivable | 216,000 |
| Inventories | 3,743,000 |
| Non Trade Receivables | — |
| Other Assets Current | 1,121,000 |
| Total Assets Current | 99,073,000 |
| Marketable Securities Non Current | 20,160,000 |
| Property Plant And Equipment | — |
| Other Assets Non Current | 361,000 |
| Total Assets Non Current | 20,521,000 |
| Total Assets | 119,594,000 |
| Accounts Payable | 3,745,000 |
| Deferred Revenue | 5,314,000 |
| Short Term Debt | — |
| Other Liabilities Current | 20,183,000 |
| Total Liabilities Current | 29,242,000 |
| Long Term Debt | — |
| Other Liabilities Non Current | 82,000 |
| Total Liabilities Non Current | 85,877,000 |
| Total Liabilities | 115,119,000 |
| Common Stock | 1,012,000 |
| Retained Earnings | -1,706,047,000 |
| Accumulated Other Comprehensive Income | -2,182,000 |
| Total Shareholders Equity | -30,038,000 |
Get over a decade of historical cash flow statement data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Depreciation And Amortization | 713,000 |
| Share Based Compensation Expense | 6,576,000 |
| Other Non Cash Income Expense | — |
| Change In Accounts Receivable | 2,543,000 |
| Change In Inventories | -5,362,000 |
| Change In Non Trade Receivables | — |
| Change In Other Assets | 902,000 |
| Change In Accounts Payable | -27,654,000 |
| Change In Other Liabilities | — |
| Cash From Operating Activities | -4,774,000 |
| Purchases Of Marketable Securities | 61,158,000 |
| Sales Of Marketable Securities | 0 |
| Acquisition Of Property Plant And Equipment | 38,000 |
| Acquisition Of Business | — |
| Other Investing Activities | — |
| Cash From Investing Activities | 35,419,000 |
| Tax Withholding For Share Based Compensation | 69,000 |
| Payments Of Dividends | — |
| Issuance Of Common Stock | 0 |
| Repurchase Of Common Stock | — |
| Issuance Of Long Term Debt | — |
| Repayment Of Long Term Debt | — |
| Other Financing Activities | — |
| Cash From Financing Activities | -86,028,000 |
| Change In Cash | -54,306,000 |
| Cash At End Of Period | 47,872,000 |
| Income Taxes Paid | 0 |
| Interest Paid | 7,830,000 |
Get over a decade of historical key metrics data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Earnings Per Share | 45.37 |
| Price To Earnings Ratio | 0.1935 |
| Earnings Growth Rate | -9,552.0833 |
| Price Earnings To Growth Ratio | -0.0 |
| Book Value Per Share | 1.1069 |
| Price To Book Ratio | 7.9324 |
| Ebitda | 192,924,000 |
| Enterprise Value | — |
| Dividend Yield | — |
| Dividend Payout Ratio | — |
| Debt To Equity Ratio | — |
| Capital Expenditures | — |
| Free Cash Flow | — |
| Return On Equity | -6.1073 |
| One Year Beta | 1.3412 |
| Three Year Beta | 1.5927 |
| Five Year Beta | 1.4159 |
Get over a decade of historical insider transactions data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| DeLucia David | Chief Financial Officer | 2026-02-03 | 26,000 | A | 26,000 |
| Wettig Thane | Director, CEO | 2026-02-03 | 60,000 | A | 60,000 |
Get over a decade of historical institutional holdings data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Corient Private Wealth LLC | 2025-12-31 | 87,914 | 10,013 | 8.78 |
| Corient Private Wealth LLC | 2025-12-31 | 87,914 | 10,013 | 8.78 |
| ADAR1 Capital Management, LLC | 2025-12-31 | 91,918 | 10,469 | 8.78 |
| CITADEL ADVISORS LLC | 2025-12-31 | 147,117 | 16,756 | 8.78 |
| BANK OF AMERICA CORP /DE/ | 2025-12-31 | 5,225 | 595 | 8.7815 |
Get over a decade of historical mutual fund holdings data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2026-01-31 | I Shares | KCXIX | 19 | 156.34 | 0.0001 |
| VANGUARD HORIZON FUNDS | 2025-12-31 | Admiral Shares | VHCAX | 2,716 | 23,846.48 | 0.0001 |
| VANGUARD HORIZON FUNDS | 2025-12-31 | Investor Shares | VHCOX | 2,716 | 23,846.48 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Select Shares | VSTSX | 114,179 | 1,002,491.62 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VSMPX | 114,179 | 1,002,491.62 | 0.0 |
